-- Dr. Reddy's Laboratories (NSE:DRREDDY, BOM:500124) has received a notice of compliance (NOC) from the Canadian regulator, Pharmaceutical Drugs Directorate (Health Canada), approving its generic Semaglutide Injection, according to a Wednesday filing to the Indian stock exchanges.
The issuance of the NOC authorizes the commercialization, sale, and distribution of the diabetes control drug Semaglutide Injection in Canada. The market authorization covers the 2 mg/ pen (in 1.34 mg / mL) and 4 mg/pen (1.34 mg / mL).
The active pharmaceutical ingredient is entirely produced in-house by Dr. Reddy's, with finished product manufacturing currently carried out by the company's manufacturing partner, OneSource Specialty Pharma (NSE:ONESOURCE, BOM:544292).
The company's shares were down nearly 1% in recent trade.